|
First-in-human dose-escalating trial of E.coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Novadaq Technologies |
Research Funding - Genentech (Inst); LI-COR Biosciences (Inst); Novadaq Technologies (Inst) |
| |
|
Leadership - PNP Therapeutics |
Stock and Other Ownership Interests - PNP Therapeutics |
Research Funding - PNP Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Southern Research Institute (Inst) |
| |
|
Stock and Other Ownership Interests - PNP Therapeutics |
Research Funding - PNP Therapeutics (Inst) |
| |
|
Research Funding - PNP Therapeutics (Inst) |
| |
|
Research Funding - PNP Therapeutics (Inst) |
| |
|
Patents, Royalties, Other Intellectual Property - PNP Therapeutics |
| |
|
Employment - PNP Therapeutics |
Leadership - PNP Therapeutics |
Stock and Other Ownership Interests - PNP Therapeutics |
Travel, Accommodations, Expenses - PNP Therapeutics |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |